Test ID: PTSE
Platinum, Serum
Secondary ID 
A test code used for billing and in test definitions created prior to November 2011
NY State Approved Indicates the status of NY State approval and if the test is orderable for NY State clients.
Useful For Suggests clinical disorders or settings where the test may be helpful
Monitoring platinum levels in patients receiving cisplatin or other platinum-containing drugs
Special Instructions and Forms Describes specimen collection and preparation information, test algorithms, and other information pertinent to test. Also includes pertinent information and consent forms to be used when requesting a particular test
Method Name A short description of the method used to perform the test
Inductively Coupled Plasma-Mass Spectrometry (ICP-MS)
Reporting Name A shorter/abbreviated version of the Published Name for a test; an abbreviated test name
Aliases Lists additional common names for a test, as an aid in searching
Platinum (Pt)
Specimen Type Describes the specimen type needed for testing
Specimen Required Defines the optimal specimen. This field describes the type of specimen required to perform the test and the preferred volume to complete testing. The volume allows automated processing, fastest throughput and, when indicated, repeat or reflex testing.
Collection Container/Tube: Plain, royal blue-top Monoject trace element blood collection tube, product #8881-307006 (Supply T184)
Submission Container/Tube: 7-mL Mayo metal-free, screw-capped, polypropylene vial (Supply T173)
Specimen Volume: 1 mL
Collection Instructions:
1. Allow the specimen to clot for 30 minutes; then centrifuge the specimen to separate serum from the cellular fraction.
2. Remove the stopper. Carefully pour specimen into a Mayo metal-free, polypropylene vial, avoiding transfer of the cellular components of blood. Do not insert a pipet into the serum to accomplish transfer, and do not ream the specimen with a wooden stick to assist with serum transfer.
3. See Metals Analysis-Collection and Transport in Special Instructions for complete instructions.
Additional Information: High concentrations of gadolinium and iodine are known to interfere with most metals tests. If gadolinium- or iodine-containing contrast media has been administered, a specimen should not be collected for 96 hours.
Specimen Minimum Volume Defines the amount of specimen required to perform an assay once, including instrument and container dead space. Submitting the minimum specimen volume makes it impossible to repeat the test or perform confirmatory or perform reflex testing. In some situations, a minimum specimen volume may result in a QNS (quantity not sufficient) result, requiring a second specimen to be collected.
Reject Due To Identifies specimen types and conditions that may cause the specimen to be rejected
| Hemolysis | Mild OK; Gross OK |
| Lipemia | Mild OK; Gross OK |
| Icterus | Mild OK; Gross OK |
| Other | NA |
Specimen Stability Information Provides a description of the temperatures required to transport a specimen to the laboratory. Alternate acceptable temperature(s) are also included.
| Specimen Type | Temperature | Time |
|---|---|---|
| Serum | Refrigerated (preferred) | 30 days |
| Ambient | 30 days | |
| Frozen | 30 days |
Clinical Information Discusses physiology, pathophysiology, and general clinical aspects, as they relate to a laboratory test
Cisplatin (cis-diamminedichloroplatinum)(1) and carboplatin (cyclobutanedicarboxylatoplatinum)(2,3) are used in cancer chemotherapy. Clinical trials demonstrate schedule-dependent activity of carboplatin in patients with relapsed and refractory acute leukemia. Patients responding to carboplatin therapy had peak serum platinum concentration in the range of 0.6 to 1.8 mcg/mL. Trough concentrations ranged from 0.1 to 0.4 mcg/mL. Platinum concentrations maintained >1.8 mcg/mL can induce neutropenia and renal failure if coadministered with nephrotoxic antibiotics.(1,2)
Unexposed individuals should have platinum concentrations <0.04 mcg/mL.(4)
Reference Values Describes reference intervals and additional information for interpretation of test results. May include intervals based on age and sex when appropriate. Intervals are Mayo-derived, unless otherwise designated. If an interpretive report is provided, the reference value field will state this.
Cisplatin Infusion, Peak: 0.6-1.8 mcg/mL
Cisplatin Infusion, Trough: 0.1-0.4 mcg/mL
Unexposed: <0.04 mcg/mL
Interpretation Provides information to assist in interpretation of the test results
Effective Range:
-Patients responding to carboplatin therapy had peak plasma platinum concentration in the range of 0.6 to 1.8 mcg/mL.
-Trough concentrations range from 0.1 to 0.4 mcg/mL.
-Platinum concentrations maintained >1.8 mcg/mL can induce neutropenia, and renal failure if coadministered with nephrotoxic antibiotics.
-Unexposed patients should have platinum concentrations <0.04 mcg/mL.
Cautions Discusses conditions that may cause diagnostic confusion, including improper specimen collection and handling, inappropriate test selection, and interfering substances
Platinum concentrations maintained >1.8 mcg/mL can induce neutropenia, and renal failure if co-administered with nephrotoxic antibiotics. The dose-limiting toxicity of carboplatin in leukemia patients was prolonged neutropenia. Other toxicities include renal failure, particularly in the setting of nephrotoxic antibiotics and amphotericin.
Interpretation requires knowledge of the time of serum collection relative to dosing. Peak platinum concentration is achieved within 30 minutes of the end of infusion, while the trough platinum concentration occurs just before the next dose.
Clinical Reference Provides recommendations for further in-depth reading of a clinical nature
1. Katano K, Tsujitani S, Oka S, et al: Pharmaocokinetics of hypotonic cisplatin chemotherapy administered into the peritoneal and pleural cavities in experimental model. Anticancer Res 2000;20:1603-1607
2. Kaufmann SJ, Karp JE, Letendre L, et al: Phase I and pharmacologic study of infusional topotecan and Carboplatin in relapsed and refractory acute leukemia. Clin Cancer Res 2005;11:6641-6649
3. Lindauer A, Eickhoff C, Kloft C et al: Population pharmacokinetics of high-dose carboplatin in children and adults. Ther Drug Monit 2010;32:159-168
Method Description Describes how the test is performed and provides a method-specific reference
This assay is performed on an inductively coupled plasma-mass spectrometer. Calibrating standards and blanks are diluted with an aqueous acidic diluent containing internal standards. Quality control specimens and patient samples are diluted in an identical manner. In turn, all diluted blanks, calibrating standards, quality control specimens, and patient specimens are aspirated into a pneumatic nebulizer and the resulting aerosol directed to the hot plasma discharge by a flow of argon. In the annular plasma the aerosol is vaporized, atomized, then ionized. The ionized gases plus neutral species formed in the annular plasma space are aspirated from the plasma through an orifice into a quadrupole mass spectrometer. The mass range from 1 to 263 amu is rapidly scanned multiple times and ion counts tabulated for each mass of interest. Instrument response is defined by the linear relationship of analyte concentrations vs. ion count ratio (analyte ion count/internal standard ion count). Analyte concentrations are derived by reading the ion count ratio for each mass of interest and determining the concentration from the response line.(Unpublished Mayo method)
Day(s) and Time(s) Test Performed Outlines the days and times the test is performed. This field reflects the day and time the sample must be in the testing laboratory to begin the testing process and includes any specimen preparation and processing time required before the test is performed. Some tests are listed as continuously performed, which means assays are performed several times during the day.
Tuesday; 3 p.m.
Analytic Time Defines the amount of time it takes the laboratory to setup and perform the test. This is defined in number of days. The shortest interval of time expressed is "same day/1 day," which means the results may be available the same day that the sample is received in the testing laboratory. One day means results are available 1 day after the sample is received in the laboratory.
Maximum Laboratory Time Defines the maximum time from specimen receipt at Mayo Medical Laboratories until the release of the test result
Specimen Retention Time Outlines the length of time after testing that a specimen is kept in the laboratory before it is discarded
Performing Laboratory Location The location of the laboratory that performs the test
Test Classification Provides information regarding the medical device classification for laboratory test kits and reagents. Tests may be classified as cleared or approved by the US Food and Drug Administration (FDA) and used per manufacturer's instructions, or as products that do not undergo full FDA review and approval, and are then labeled as an Analyte Specific Reagent (ASR), Investigation Use Only (IUO) product, or a Research Use Only (RUO) product.
CPT Code Information Provides guidance in determining the appropriate Current Procedural Terminology (CPT) code(s) information for each test or profile. The listed CPT codes reflect Mayo Medical Laboratories interpretation of CPT coding requirements. It is the responsibility of each laboratory to determine correct CPT codes to use for billing.
83789
LOINC® Code Information Provides guidance in determining the Logical Observation Identifiers Names and Codes (LOINC) values for the result codes returned for this test or profile.
| Result ID | Reporting Name | LOINC Code |
|---|---|---|
| 61749 | Platinum, S | 5714-1 |
External
link
PDF
document
Excel
document
Word
document